Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Waldenstrom's Macroglobulinemia Clear all
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

NCT02092909
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
IMO-8400
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

NCT00062244
View directory record Official record
Conditions
Waldenström Macroglobulinemia
Interventions
oblimersen sodium
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

NCT00811733
View directory record Official record
Conditions
Waldenstrom Macroglobulinaemia
Interventions
Ofatumumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 10, 2026, 1:46 PM EDT
Recruiting Not applicable Interventional

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

NCT05643235
View directory record Official record
Conditions
Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 1 Interventional Results available

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

NCT01078974
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
pomalidomide, dexamethasone, rituximab
Drug
Lead sponsor
Steven P. Treon, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

Simvastatin in Waldenstrom's Macroglobulinemia

NCT00575965
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Simvastatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00045695
View directory record Official record
Conditions
Lymphoma
Interventions
bortezomib
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Hinsdale, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

NCT05360238
View directory record Official record
Conditions
Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory, Chronic Lymphoid Leukemia in Relapse, B-cell Lymphoma Refractory
Interventions
MB-106
Biological
Lead sponsor
Mustang Bio
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Orange, California • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

NCT02566265
View directory record Official record
Conditions
Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions
Fluzone High Dose Vaccine, Standard of care/Placebo
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00020800
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, fludarabine phosphate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

NCT02400437
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Ixazomib, Dexamethasone, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

NCT00422656
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Perifosine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

NCT00150462
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
Beverly Hills, California • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

NCT00976248
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
RAD001
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

NCT01614821
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
PCI-32765
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

NCT01470196
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Dexamethasone, Carfilzomib, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

NCT00060346
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
153
States / cities
Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 10, 2026, 1:46 PM EDT
Not yet recruiting Phase 2 Interventional

Teclistamab In Waldenstrom's Macroglobulinemia

NCT07791498
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Teclistamab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 10, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

NCT00492050
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Bortezomib, Rituximab, Valacyclovir
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00005609
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
66
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 10, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

NCT00667329
View directory record Official record
Conditions
Lymphoma
Interventions
2CdA, Cyclophosphamide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 1 Interventional

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

NCT01744912
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Ublituximab, Lenalidomide
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Huntsville, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

NCT00113802
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Epratuzumab (hLL2- anti-CD22 humanized antibody)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 10, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

NCT00142168
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
CC-5103 (lenalidomide), Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 10, 2026, 1:46 PM EDT